Evidence map›Paper›PMID 36263650›Full record

ArticleClinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology2022

Hydroxychloroquine, Interleukin-6 Receptor Antagonists and Corticoid Treatments of Acute COVID-19 Infection: Psychiatric Symptoms and Mental Disorders 4 Months Later.

Matthieu Gasnier, Walid Choucha, David Montani, Nicolas Noël, Céline Verstuyft, Francois Radiguer, Xavier Monnet, Laurent Becquemont, Emmanuelle Corruble, Romain Colle and 1 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. [Post-COVID-19 syndrome].Bulletin de l'Academie nationale de medecine · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Matthieu GasnierDepartment of Psychiatry, Bicêtre Hospital, Mood Center Paris Saclay, AP-HP, Paris-Saclay University, Le Kremlin Bicêtre, France.ORCID https://orcid.org/0000-0003-4887-4025
Walid ChouchaDepartment of Psychiatry, Bicêtre Hospital, Mood Center Paris Saclay, AP-HP, Paris-Saclay University, Le Kremlin Bicêtre, France.ORCID https://orcid.org/0000-0002-0344-2256
David MontaniDepartment of Pneumology, Bicêtre Hospital, AP-HP, Paris-Saclay University, Inserm UMR_S999, Le Kremlin Bicêtre, France.ORCID https://orcid.org/0000-0002-9358-6922
Nicolas NoëlORCID https://orcid.org/0000-0003-4055-617X
Céline VerstuyftMOODS Team, INSERM 1018, CESP, Paris-Saclay University, Le Kremlin Bicêtre, France.ORCID https://orcid.org/0000-0002-8534-224X
Francois RadiguerPost-surgical Intensive Care Unit, Bicêtre Hospital, AP-HP, Paris-Saclay University, Inserm UMR_S999, Le Kremlin Bicêtre, France.ORCID https://orcid.org/0000-0002-4267-4308
Xavier MonnetIntensive Care Unit, Bicêtre Hospital, AP-HP, Paris-Saclay University, Inserm UMR_S999, FHU SEPSIS, Le Kremlin Bicêtre, France.ORCID https://orcid.org/0000-0001-6820-2678
Laurent BecquemontMOODS Team, INSERM 1018, CESP, Paris-Saclay University, Le Kremlin Bicêtre, France.ORCID https://orcid.org/0000-0003-3477-8956
Emmanuelle CorrubleDepartment of Psychiatry, Bicêtre Hospital, Mood Center Paris Saclay, AP-HP, Paris-Saclay University, Le Kremlin Bicêtre, France.ORCID https://orcid.org/0000-0002-9441-6079
Romain ColleDepartment of Psychiatry, Bicêtre Hospital, Mood Center Paris Saclay, AP-HP, Paris-Saclay University, Le Kremlin Bicêtre, France.ORCID https://orcid.org/0000-0002-2549-4495
COMEBAC Study Group
Inserm · FRCommissariat à l'Énergie Atomique et aux Énergies Alternatives · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Psychiatric symptoms and mental disorders are common after Coronavirus Disease-19 (COVID-19). Some drugs used to treat acute COVID-19 have psychiatric side effects. We assessed the psychiatric symptoms and mental disorders of patients treated for acute COVID-19 with hydroxychloroquine (HCQ), interleukin-6 receptor antagonists (anti-IL-6), and corticoids (CTC). Methods: We evaluated 177 patients in a day hospital 4 months after acute infection. Results: In a multivariate analysis, HCQ was associated with significant anxiety symptoms (odds ratio [OR] = 5.9, 95% confidence interval [95% CI] = 1.8-20.0, Conclusion: We recommend monitoring psychiatric symptoms, especially anxiety, in patients treated with HCQ during COVID-19 infection. Further studies with larger samples and prospective assessments are needed to confirm our results.

Indexed as

AnxietyCOVID-19Major depressive disorder

Identifiers

PMID36263650
PMCPMC9606425
OpenAlexW4306912579

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.